[Increased knowledge on familial melanoma and the underlying genetics]

Area of Science:

• Genetics
• Oncology
• Dermatology

Background:

• Familial melanoma accounts for 5-10% of cases.
• Germline mutations, particularly in CDKN2A, are found in 5-20% of melanoma families.
• Many melanoma families do not have identified high-risk germline mutations.

Purpose of the Study:

• To increase knowledge on familial melanoma and its underlying genetic factors.
• To identify genetic mutations associated with melanoma risk.
• To inform clinical follow-up strategies for melanoma families.

Main Methods:

• Review of genetic studies on familial melanoma.
• Analysis of germline mutations in genes like CDKN2A, CDK4, TERT, POT1, ACD, TERF2IP, and BAP1.
• Investigation of common variants in pigmentation pathway genes (MC1R, ASIP, IRF4, TYR, TYRP1, OCA).

Main Results:

• Swedish CDKN2A mutation carriers exhibit early melanoma onset, increased risks of multiple primary melanomas, tobacco-associated cancers, and worse survival.
• Mutations in other genes (CDK4, TERT, POT1, ACD, TERF2IP, BAP1) are identified in some non-Swedish and Swedish melanoma families.
• Common variants in pigmentation genes are associated with varying melanoma risks.

Conclusions:

• Familial melanoma has a complex genetic basis, with CDKN2A being a significant but not the sole determinant.
• Individuals in melanoma families require regular dermatologic surveillance.
• Genetic testing and tailored follow-up are crucial for individuals with known mutations in tumor suppressor genes like CDKN2A and BAP1, extending to other cancer risks.